PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 19, 2026Science Immunology1 citations

The autoantigen TRIM21 assembles proinflammatory immune complexes after lytic cell death

View Full Paper
EEEsther L. Jones EvansBDBenjamin DemarcoHCHan Cai

Key Points

  • The research aims to explore how TRIM21 functions as an autoantigen following cell death in Sjögren's disease.
  • Analyzed the release of TRIM21 after various forms of cell death (pyroptosis and necroptosis) but not apoptosis.
  • Examined the formation of immune complexes involving TRIM21 and antibodies in Sjögren's disease.
  • Investigated the uptake of TRIM21 immune complexes by macrophages and their inflammatory responses.
  • TRIM21 is released during lytic cell death and forms immune complexes with antibodies.
  • These immune complexes bind to macrophages, leading to enhanced proinflammatory responses.
  • High levels of TRIM21 and associated autoantibodies are observed in Sjögren’s disease.

Abstract

Sjögren’s disease (SjD) causes localized and systemic inflammation and autoantibody production against intracellular proteins such as TRIM21/Ro52 (tripartite motif-containing protein 21). TRIM21, an E3 ubiquitin ligase, binds antibody Fc domains on opsonized pathogens that have escaped extracellular immunity and entered the cytosol. TRIM21 then ubiquitinates these pathogens, driving their proteasomal degradation. How TRIM21 becomes an autoantigen remains unclear. We show that TRIM21 is released upon lytic cell death (pyroptosis or necroptosis) but not apoptosis. Although many cytosolic proteins are released by dead cells, liberated TRIM21 is distinct: Its high antibody affinity enables binding to Fc domains of circulating immunoglobulins, forming large immune complexes (ICs). These ICs increase in SjD, where anti-TRIM21 autoantibodies interact with released TRIM21 via Fc and F(ab′) 2 . TRIM21 ICs are taken up by macrophages, which drive proinflammatory responses, antigen presentation, and metabolic changes in high interferon environments. Thus, TRIM21 may perpetuate inflammation and autoantigen presentation, resulting in high immunogenicity.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Evans et al. (2026) studied this question.

synapsesocial.com/papers/69e473de010ef96374d8fad4https://doi.org/10.1126/sciimmunol.ads9680
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1TRIM21—From Intracellular Immunity to Therapy2019 · 153 citations
  2. 2QuPath: Open source software for digital pathology image analysis2017 · 9,053 citations
  3. 3Actin polymerization. The mechanism of action of cytochalasin D.1986 · 287 citations
  4. 4STAR: ultrafast universal RNA-seq aligner2012 · 57,691 citations
  5. 5Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis2003 · 545 citations